Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that could end up competing with Zepbound from Eli Lilly.
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
Could Viking Therapeutics Become the Next Novo Nordisk?
Viking Therapeutics has a high valuation for a company with no sales. Novo Nordisk is competing in the same market, and that market is growing rapidly.
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
Viking Therapeutics has a powerful weight loss candidate in late-stage trials. Zealand Pharma has a handful of programs and a powerful collaborator.
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
The upstart biotech just reported its Q2 earnings -- and investors were pleased. All of its programs are proceeding according to plan, and it isn't spending much.
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Artificial intelligence (AI) chip leader Nvidia has soared 126% so far this year -- but this biotech stock has advanced even more. This biotech player is targeting a market that could be worth $100 billion by the end of the decade.
Is Viking Therapeutics a Millionaire-Maker Stock?
Viking is developing drug candidates in an area of high interest and growth: weight loss. The company is launching a phase 3 clinical trial for its first weight loss candidate.
Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
Eli Lilly (LLY) and Novo Nordisk (NVO) shares lost ground, while shares of drugmaker Viking Therapeutics (VKTX) soared in intraday trading Thursday after the company reported advances in trials of its weight-loss drugs that could challenge the dominance of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community.
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
Why Viking Therapeutics Stock Is Skyrocketing Today
Viking Therapeutics plans to advance its obesity drug VK2735 into late-stage clinical testing. VK2735 could be a formidable rival to Lilly's Zepbound and Novo Nordisk's Wegovy if it's approved.
